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PAcute Myocardial Infarction
Multiple Biomarkers at Admission
Significantly Improve the Prediction
of Mortality in Patients Undergoing Primary
Percutaneous Coronary Intervention for Acute
ST-Segment Elevation Myocardial Infarction
Peter Damman, MD, Marcel A. M. Beijk, MD, Wichert J. Kuijt, MD, Niels J. W. Verouden, MD,
Nan van Geloven, MSC, José P. S. Henriques, MD, PHD, Jan Baan, MD, PHD, Marije M. Vis, MD,
Martijn Meuwissen, MD, PHD, Jan P. van Straalen, Johan Fischer, PHD, Karel T. Koch, MD, PHD,
Jan J. Piek, MD, PHD, Jan G. P. Tijssen, PHD, Robbert J. de Winter, MD, PHD
Amsterdam, the Netherlands
Objectives We investigated whether multiple biomarkers improve prognostication in ST-segment elevation myocardial in-
farction (STEMI) patients undergoing primary percutaneous coronary intervention.
Background Few data exist on the prognostic value of combined biomarkers.
Methods We used data from 1,034 STEMI patients undergoing primary percutaneous coronary intervention in a high-
volume percutaneous coronary intervention center in the Netherlands and investigated whether combining
N-terminal pro-brain natriuretic peptide, glucose, C-reactive protein, estimated glomerular filtration rate, and car-
diac troponin T improved the prediction of mortality. A risk score was developed based on the strongest predict-
ing biomarkers in multivariate Cox regression. The additional prognostic value of the strongest predicting
biomarkers to the established prognostic factors (age, body weight, diabetes, hypertension, systolic blood pressure,
heart rate, anterior myocardial infarction, and time to treatment) was assessed in multivariable Cox regression.
Results During follow-up (median, 901 days), 120 of the 1,034 patients died. In Cox regression, glucose, estimated glo-
merular filtration rate, and N-terminal pro-brain natriuretic peptide were the strongest predictors for mortality
(p  0.05, for all). A risk score incorporating these biomarkers identified a high-risk STEMI subgroup with a signifi-
cantly higher mortality when compared with an intermediate- or low-risk subgroup (p  0.001). Addition of the 3 bio-
markers to established prognostic factors significantly improved prediction for mortality, as shown by the net reclassi-
fication improvement (0.494, p  0.001) and integrated discrimination improvement (0.0295, p  0.01).
Conclusions Our data suggest that addition of a multimarker to a model including established risk factors improves the pre-
diction of mortality in STEMI patients undergoing primary percutaneous coronary intervention. Furthermore, the
use of a simple risk score based on these biomarkers identifies a high-risk subgroup. (J Am Coll Cardiol 2011;
57:29–36) © 2011 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.06.053c
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egment elevation myocardial infarction (STEMI). Despite
he improvement in both morbidity and mortality in these
atients, groups at high risk of complications and adverse
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rom additional mechanical and pharmacological measures
btained during and after PPCI. The ability to differentiate
etween patients at high and low risk may be a valuable tool
o optimize the use of adjunctive therapies, which may
mprove outcomes.
See page 37
Several demographic, electrocardiographic, and percu-
aneous coronary intervention (PCI)-related characteris-
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Multimarker Improves Prognostication in STEMI December 28, 2010/January 4, 2011:29–36tics have been identified as impor-
tant prognostic factors regarding
mortality in patients with STEMI
(1). Furthermore, novel biomark-
ers such as N-terminal pro-brain
natriuretic peptide (NT-proBNP)
(2), glucose (3), C-reactive protein
(CRP) (4), creatinine or estimated
glomerular filtration rate (eGFR)
(5), and cardiac troponin T
(cTnT) (6) have been reported to
be associated with an increased
risk for mortality in STEMI pa-
tients. These biomarkers reflect
left ventricular dysfunction, glu-
cose metabolism, inflammation
status, renal function, and myocar-
dial cell damage, respectively.
Consequently, a multimarker
approach may yield valuable prog-
nostic information for STEMI
patients undergoing PPCI, and a
simple multimarker risk score
ould be of particular value for fast, early assessment of
aseline risk. We investigated whether multiple biomarkers,
ither alone or in combination with established risk factors,
mproved prognostication in STEMI patients who under-
ent PPCI using a large database from a high-volume PCI
enter in the Netherlands.
ethods
ource population and procedures. We used data from
onsecutive STEMI patients who underwent PPCI in our
enter between January 1, 2005, and January 5, 2007. The
PCI and adjunctive pharmacological treatment was per-
ormed according to the American College of Cardiology/
merican Heart Association and European Society of
ardiology guidelines. In general, patients were eligible for
PCI if they had ischemic chest pain, onset of symptoms no
ater than 12 h, and at least 1 mm of ST-segment elevation
n 2 contiguous leads on the 12-lead electrocardiogram.
atients received aspirin (500 mg), clopidogrel (300 to 600
g), and unfractionated heparin (5,000 IU). Glycoprotein
Ib/IIIa inhibitors were used at the discretion of the
perator. If a coronary stent was implanted, clopidogrel was
rescribed for 1 month or more to patients with a bare-
etal stent and for 6 months or more after a drug-eluting
tent.
iomarkers. Blood samples were obtained before PPCI as
art of routine clinical care. Blood samples were drawn
mmediately after insertion of the arterial sheath before
PCI for assessment of cTnT, CRP, glucose, NT-proBNP,
nd plasma creatinine. Blood samples were centrifuged
ithout undue delay and analyzed. Both cTnT and NT-
Abbreviations
and Acronyms
CRP  C-reactive protein
cTnT  cardiac troponin T
eGFR  estimated
glomerular filtration rate
HR  hazard ratio
IDI  integrated
discrimination improvement
MI  myocardial infarction
NRI  net reclassification
improvement
NT-proBNP  N-terminal
pro-brain natriuretic peptide
PCI  percutaneous
coronary intervention
PPCI  primary
percutaneous coronary
intervention
STEMI  ST-segment
elevation myocardial
infarctionroBNP were measured using a Hitachi modular E-170 mnalyzer (Roche Diagnostics GmbH, Mannheim, Germany).
RP was measured with an immunoturbidimetric assay on a
itachi modular P-800 (Roche Diagnostics GmbH). Glucose
nd plasma creatinine were measured with an enzymatic assay
n a Hitachi modular P-800 analyzer (Roche Diagnostics
mbH). The eGFR was calculated according to the Cockcroft
nd Gault formula (7).
ata collection. Our local catheterization laboratory data-
ase was consulted for information about patients’ demograph-
cs and about procedural and angiographic characteristics that
ad been collected prospectively and entered by interventional
ardiologists and specialized nurses. Patients were surveyed at 1
ear after PPCI using a mailed questionnaire.
tudy population. For the current analysis, we included all
TEMI patients who underwent PPCI between January 1,
005, and January 5, 2007, and for whom complete and
alid laboratory measurements obtained before PCI were
vailable. Only the first PPCI was included in the case of a
atient with multiple PPCIs within the study period. We
xcluded STEMI patients with cardiogenic shock (n  85)
nd patients undergoing rescue PCI after failed thrombol-
sis (n  10) (8).
ain outcome measure. The main outcome measure for
ur current analysis was all-cause mortality before Novem-
er 6, 2008. Information on vital status obtained from the
nstitutional database was synchronized with the Dutch
ational population registry and was verified until Novem-
er 6, 2008.
tatistical analysis. Normally distributed continuous vari-
bles were compared with the Student t test and skewed-
istributed with the Wilcoxon rank-sum test. Categorical
ariables were compared with the chi-square test. The
rognostic value of the biomarkers was assessed by investi-
ating the relationship between mortality and biomarkers in
sets of Cox proportional-hazards analyses: univariate
nalyses of single biomarkers and multivariate analysis
ncluding all biomarkers (multimarker). The univariate
nalyses were used to determine cutoff values for the
iomarkers. These cutoff values were based on the quartiles
f the individual biomarker levels. When hazard did not
iffer significantly between adjacent quartiles, as indicated
y the p value from the Cox model, these were merged.
A multivariate model initially was developed incorporat-
ng the 5 biomarkers. Biomarkers with p  0.05 by the
ald test were identified by backward selection. From the
nal model, a simplified score was obtained by putting
eights to individual biomarkers proportional to the hazard
atio (HR) coefficients. The multimarker risk score was
efined as the sum of these points, with higher points
ndicating a higher mortality risk. Cutoffs for low-,
ntermediate-, and high-risk groups were determined ac-
ording to thirds of risk among those who died. Cumulative
vent rates were estimated with the Kaplan-Meier method
nd were compared with the log-rank test.
The additional prognostic value of the biomarkers in the
ultimarker risk score to established prognostic factors was
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December 28, 2010/January 4, 2011:29–36 Multimarker Improves Prognostication in STEMIssessed in a multivariate Cox proportional-hazards model.
his model included the following established prognostic
actors derived from the TIMI score: age, body weight
body mass index), history of diabetes or hypertension,
ystolic blood pressure and heart rate, anterior myocardial
nfarction (MI), and time to treatment (symptom onset to
rst balloon inflation) (1,9). The increased discriminative
alue after addition of the biomarkers to the established
rognostic factors was estimated using 3 measures: the
arrell’s C index, net reclassification improvement (NRI),
nd integrated discrimination improvement (IDI). The
arrell’s C index is defined as the proportion of usable
atients pairs in which the predictions and outcomes are
oncordant (10). The NRI and IDI were calculated by
nalyzing the differences in patients’ individual estimated
robability of mortality after addition of a single or multiple
iomarkers to a model containing the aforementioned estab-
ished prognostic factors (11). Because no prior risk categories
xist for 2-year mortality, we chose Harrell’s implementation of
he NRI, where the combination of any improved and wors-
ned probability results in the categoryless NRI (Fig. 1). Thus,
he reported NRI indicates relatively how many patients
mprove their predicted probability for mortality. The IDI
onsiders the change in the estimated prediction probabilities
s a continuous variable and represents the average improve-
ent in predicted probability. The NRI and IDI were calcu-
ated in patients with complete follow-up at 2 years.
The proportional-hazards assumptions of all analyses
ere assessed with Schoenfeld’s tests. No relevant violations
ere observed.
Figure 1 Flowchart for Determining the Net Reclassification Im
The net reclassification improvement for biomarker X is calculated as the summed
minus the proportions of patients with a worsened prediction after addition of theesults
total of 1,340 consecutive STEMI patients underwent
PCI at our institution between January 1, 2005, and
anuary 5, 2007. We excluded 306 patients because of
issing or incomplete biomarkers. The baseline character-
stics of the 1,034 included patients who had complete and
alid biomarker measurements are shown in Table 1. The
ean age in our study population was 62 years, and 73%
ercent were male. The baseline characteristics of the
ncluded and excluded patients were comparable. There
ere clinically small, but statistically significant, differences
n hypercholesterolemia, history of coronary artery bypass
rafting, and prevalence of anterior MI. During a median
ollow-up time of 901 days (interquartile range: 758 to
,122 days), 120 patients died (cumulative event rate:
4.1%). All patients were identified in the national popula-
ion registry.
nivariate analyses. In the univariate analyses, death rates
ncreased significantly with increasing levels of the bio-
arkers cTnT, CRP, glucose, NT-proBNP, and eGFR
Table 2). The details of determining the cutoff values are
hown in the Online Appendix. Generally, the lowest 2
uartiles were merged because of comparable HR
oefficients.
ultimarker score. The multivariate analyses are shown in
able 3. cTnT and CRP were not associated with an
ncreased mortality and were excluded from the final model.
ithin the final model, an eGFR of 90 ml/min, NT-
roBNP of 150 ng/l or more, and glucose of 8 mmol/l or
ore all were associated with significantly higher mortality
ment
rtions of patients with an improved prediction
rker to the multivariable Cox proportional hazards model.prove
propo
bioma
h
t
m
6
m
a
e; NT-pr
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Multimarker Improves Prognostication in STEMI December 28, 2010/January 4, 2011:29–36azards (p  0.05, for all). Based on the HR coefficients of
he final multivariate model (Table 3), glucose of 8 to 9
mol/l, NT-proBNP of 150 to 600 ng/l, and an eGFR of
Baseline Characteristics of the Study PopulatioTable 1 Baseline Characteristics of the Stu
Characteristics
Study P
(n 
Demographics
Age (yrs) 62
Male sex 753 (7
Body mass index 26.7
Risk factors
Current smoking 444 (4
Hypertension 318 (3
Hypercholesterolemia 236 (2
Diabetes mellitus 135 (1
Clinical history
Myocardial infarction 138 (1
Percutaneous coronary intervention 98 (9
Coronary artery bypass grafting 24 (2
Laboratory assessments
Troponin T (g/l) 0.05 (0
Glucose (mmol/l) 8.8
NT-proBNP (ng/l) 149 (5
eGFR (ml/min) 105
CRP (mg/l) 3.2 (1
Time to treatment (min) 185 (1
TIMI risk score factors
Anterior myocardial infarction 426 (4
Systolic blood pressure 132
Heart rate 77
Data are presented as mean  SD, absolute n (%), or median (interqu
CRP C-reactive protein; eGFR estimated glomerular filtration rat
In Myocardial Infarction.
Hazard Ratios for Mortality for the Individual BiomarTable 2 Hazard Ratios for Mortality for the Indiv
Biomarker
Mor
% (n/N)
Troponin T (g/l)
0.05 8.8 (38/510)
0.05–0.23 16.4 (33/253)
0.24 20.2 (49/261)
Glucose (mmol/l)
8 7.6 (33/509)
8–9 14.7 (36/289)
10 27.3 (51/236)
NT-proBNP (ng/l)
150 6.9 (25/521)
150–599 16.1 (32/254)
600 27.0 (63/259)
eGFR (ml/min)
90 6.4 (36/640)
60–89 18.5 (36/263)
60 43.4 (48/131)
CRP (mg/l)
7 11.2 (68/756)
7 22.5 (52/278)CI  confidence interval; other abbreviations as in Table 1.0 to 89 ml/min were assigned 2 points; glucose of 10
mol/l or more and NT-proBNP of 600 ng/l or more were
ssigned 3 points; and an eGFR of 60 ml/min was
Excluded Patientspulation and Excluded Patients
tion
)
Excluded Patients
(n  306) p Value
62 13 0.69
215 (70%) 0.38
26.3 3.9 0.15
119 (38.9%) 0.05
91 (29.7%) 0.74
50 (16.3%) 0.02
30 (9.8%) 0.21
43 (14.1%) 0.75
23 (7.5%) 0.29
15 (4.9%) 0.02
24) 0.04 (0.04–0.16) 0.10
9.3 4.3 0.23
) 215 (74–820) 0.10
103 27 0.89
) 3.4 (1.5–7.7) 0.67
9) 191 (130–264) 0.83
104 (34.0%) 0.02
131 31 0.36
77 19 0.85
ange).
oBNP N-terminal pro-brain natriuretic peptide; TIMI Thrombolysis
n Univariate Cox RegressionBiomarkers in Univariate Cox Regression
(n  1,034)
p ValueHazard Ratio (95% CI)
Reference
1.73 (1.09–2.76) 0.02
2.78 (1.82–4.24) 0.001
Reference
2.00 (1.25–3.21) 0.01
3.68 (2.38–5.71) 0.001
Reference
2.73 (1.62–4.61) 0.001
5.93 (3.73–9.43) 0.001
Reference
2.59 (1.63–4.11) 0.001
8.11 (5.26–12.50) 0.001
Reference
2.23 (1.55–3.19) 0.001n anddy Po
opula
1,034
 13
3%)
 4.2
2.9%)
0.8%)
2.8%)
3.1%)
3.3%)
.5%)
.3%)
.04–0.
 3.3
6–604
 40
.4–7.7
32–26
1.2%)
 28
 18
artile rkers iidual
tality
a
T
m
6
i
o
t
0
B
j
a
(
2
i
m
H
*
b cal diffe
les 1 a
M
A
33JACC Vol. 57, No. 1, 2011 Damman et al.
December 28, 2010/January 4, 2011:29–36 Multimarker Improves Prognostication in STEMIssigned 4 points. The multimarker risk score is shown in
able 4. The Kaplan-Meier curves of the low-risk (multi-
arker score 4), intermediate-risk (multimarker score 5 or
), and the high-risk (multimarker score6) groups are shown
n Figure 2. Higher mortality at the end of follow-up was
bserved in the high-risk group (42.0%) when compared with
he intermediate-risk (17.4%) or low-risk (5.8%) groups (p 
.001, log-rank test for all pair wise comparisons).
azard Ratios for Mortality in the Multimarker and Adjusted MultimTable 3 Hazard Ratios for Mortality in the Multimarker and Adj
Multimarker
Multimarker Model
(n  1,034)
Hazard Ratio (95% CI) p Value Haz
Troponin T (g/l)
0.05 Reference
0.05–0.23 1.16 (0.71–1.89) 0.55
0.24 1.41 (0.87–2.28) 0.17
Glucose (mmol/l)
8 Reference
8–9 1.92 (1.19–3.10) 0.01 1
10 2.77 (1.76–4.34) 0.001 2
NT-proBNP (ng/l)
150 Reference
150–599 1.55 (0.87–2.75) 0.14 1
600 2.75 (1.54–4.94) 0.001 3
eGFR (ml/min)
90 Reference
60–89 1.81 (1.12–2.92) 0.02 1
60 3.94 (2.37–6.42) 0.001 3
CRP (mg/l)
7 Reference
7 1.18 (0.80–1.73) 0.41
Adjusted for age, BMI, history of diabetes or hypertension, systolic blood pressure and pulse, a
ecause of missing values. Besides more prior CABGs in excluded patients (p  0.01), no statisti
BMI  body mass index; CABG  coronary artery bypass grafting; other abbreviations as in Tab
ultimarker Risk Score for MortalityTable 4 Multimarker Risk Score for Mortality
Biomarker Add to Score
Glucose (mmol/l)
8 0
8–9 2
10 3
NT-proBNP (ng/l)
150 0
150–599 2
600 3
eGFR (ml/min)
90 0
60–89 2
60 4
Total score
Total score
4 Low risk
5–6 Intermediate risk
6 High riskbbreviations as in Table 1.iomarkers and established prognostic factors. After ad-
ustment for established risk factors, eGFR, NT-proBNP,
nd glucose remained significant predictors for mortality
Table 3). An eGFR of 60 ml/min was associated with a
.80 increased mortality hazard (HR: 2.80; 95% confidence
nterval: 1.28 to 6.09; p  0.01). Glucose of 10 mmol/l or
ore (HR: 2.42; 95% confidence interval: 1.36 to 4.33; p 
r Modelultimarker Model
Mortality
Adjusted Multimarker Model*
(n  755)
tio (95% CI) p Value Hazard Ratio (95% CI) p Value
rence Reference
.21–3.13) 0.01 1.82 (1.02–3.28) 0.05
.81–4.43) 0.001 2.42 (1.36–4.33) 0.01
rence Reference
.00–3.04) 0.05 1.61 (0.85–3.02) 0.14
.05–5.82) 0.001 2.13 (1.14–4.00) 0.02
rence Reference
.12–2.93) 0.01 1.69 (0.87–3.28) 0.12
.32–6.26) 0.001 2.80 (1.28–6.09) 0.01
myocardial infarction, and time to treatment. Two hundred seventy-nine patients were excluded
rences in baseline characteristics were observed when compared with the included patients.
nd 2.
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Figure 2 Kaplan-Meier Mortality
Curves According to Risk Group
High-risk (multimarker score 6), intermediate-risk (multimarker score 5 or 6),
and low-risk (multimarker score 4) groups. Shown are Kaplan-Meier
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Multimarker Improves Prognostication in STEMI December 28, 2010/January 4, 2011:29–36.01) was associated with higher mortality at the end of
ollow-up. Finally, a 2-fold increase in mortality was ob-
erved with NT-proBNP values of 600 ng/l or more
p 0.02). Adding eGFR, NT-proBNP, and glucose to the
stablished risk factors improved the prediction of mortality,
s shown by the increase in the Harrell’s C index (Table 5).
eclassification of patients who died or were alive at
ollow-up is presented by the NRI. Addition of each single
iomarker or the 3 markers from our score significantly
mproved the reclassification of patients (p  0.001). The
ntegrated discrimination improved significantly after addi-
ion of NT-proBNP, eGFR, or the 3 markers.
Because we hypothesized that the relationship between
dmission glucose levels and mortality differed between
iabetics and nondiabetics, we assessed the interaction
etween glucose and diabetes by testing the significance of
his relation in the Cox proportional-hazards model with
stablished risk factors. No interaction was observed (p 
.11).
iscussion
everal inferences can be drawn from the current study.
irst, within multivariate analyses, glucose, NT-proBNP,
nd eGFR were the strongest predicting biomarkers of
ortality. In contrast, cTnT and CRP were not predictive
n the multivariate analyses. Incorporation of the 3 predic-
ive biomarkers in the multimarker risk score yields impor-
ant information regarding baseline risk and mortality.
mportantly, as can be seen from Figure 2, the increased
ortality occurs early, and additional therapies to improve
utcome should start as early as possible, preferably already
uring or immediately after PPCI. Finally, in our real-world
ohort of STEMI patients undergoing PPCI, the addition
f eGFR, NT-proBNP, and glucose to a model including
stablished prognostic factors provided incremental prog-
ostic information regarding mortality. This improvement
as indicated to be statistically significant by the increase in
he NRI and IDI.
revious multimarker studies. To the best of our knowl-
iscrimination of Cox Regression Models in Predicting Mortality inTable 5 Discrimination of Cox Regression Models in Predicting
Risk Factors and Biomarkers Harrell’s C Index
Established risk factors 0.77
Established risk factors plus troponin T 0.78
Established risk factors plus glucose 0.79
Established risk factors plus NT-proBNP 0.78
Established risk factors plus eGFR 0.78
Established risk factors plus CRP 0.77
Established risk factors plus glucose, NT-proBNP, eGFR 0.81
he NRI was defined as (pimproved_prediction_among_deceased pimproved_prediction_among_alive) (pworse
efined as (ideath (pnew(i)  pold(i))/n (deceased))  (
j
alive (pnew(j)  pold(j))/n (alive)), where p
Abbreviations as in Table 1.dge, this is one of the first studies to evaluate a multimarker approach for the prediction of baseline risk of long-term
eath in patients undergoing PPCI for STEMI. In another
tudy of 298 patients receiving revascularization or throm-
olysis for MI, a multimarker approach with NT-proBNP,
RP, matrix metalloproteinase-9, pregnancy-associated
lasma protein A, myeloperoxidase, soluble CD40 ligand,
nd fibrin monomer rendered no additional prognostic
nformation beyond conventional risk stratification tools
12). A key factor in explaining these different results may
e the timing of biomarker assessment. In our study, blood
amples were obtained before PPCI. In the study by
rügger-Andersen et al. (12), blood samples were obtained
to 6 days after the index event. It is likely that biomarker
evels have been influenced by the index MI and treatment.
In a community-based cohort of elderly men with or
ithout cardiovascular disease, a multimarker approach sub-
tantially improved the prediction of death (13). In this study,
ddition of individual biomarkers to established risk factors did
ot result in an improved prediction of mortality. However,
ddition of a multimarker significantly increased the prediction
f mortality, supporting our rationale of adding a combination
f biomarkers to improve risk stratification.
GFR, glucose, and NT-proBNP. Our data emphasize
he importance of renal disease, estimated by GFR, as a risk
actor for mortality after MI. An eGFR of 60 ml/min was
ssociated with an approximately 3- to 4-fold higher mor-
ality hazard. Possible mechanisms by which renal dysfunc-
ion increases mortality risk are progressive renal decline, a
igh prevalence of coronary risk factors among patients with
hronic kidney disease, and so-called therapeutic nihilism
5). Further research may focus on the effect of reperfusion
herapy on renal function, as well as the efficacy and safety
f cardiovascular medication in these patients. This is
articularly important when realizing that renal dysfunction
as been an exclusion criterion in most clinical trials.
Numerous studies have identified admission glucose as a
redictor of adverse outcomes after acute coronary syn-
romes (14). However, uncertainty remains regarding
hether glucose is a direct mediator of adverse outcomes or
I Patientstality in STEMI Patients
Discrimination
t Reclassification
Improvement p Value
Integrated Discrimination
Improvement p Value
Reference Reference
0.388 0.01 0.0001 0.96
0.484 0.001 0.0057 0.25
0.554 0.001 0.0111 0.01
0.345 0.01 0.0193 0.04
0.375 0.01 0.0047 0.09
0.494 0.001 0.0295 0.01
iction_among_deceased pworsened_prediction_among_alive), where p proportion of patients. The IDI was
cted probability of mortality.STEMMor
Ne
ned_predn indicator of greater disease severity. Possible pathophys-
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December 28, 2010/January 4, 2011:29–36 Multimarker Improves Prognostication in STEMIological mechanisms that may be responsible for the
ncreased mortality with hyperglycemia are direct detrimen-
al effects on ischemic myocardium, microvascular dysfunc-
ion, increased inflammation, a prothrombotic state, and an
mpaired myocardial glucose utilization (14). The pro-
hrombotic state with hyperglycemia seems to result from a
ombination of increased thrombin generation and platelet
ctivation as well as inhibited fibrinolysis (15). A better
nderstanding of the above-mentioned mechanisms could
ead to specific intervention to improve the prognosis
egarding mortality.
Finally, NT-proBNP levels, determined by left ventricu-
ar function and extent of myocardial ischemia, have been
hown to predict mortality better then established risk
actors (2). Importantly, previous MI, being a determinant
f left ventricular function, was not included in our adjusted
ultimarker model. We included prior MI in exploratory
nalyses to make a fairer evaluation of NT-proBNP, and
his did not materially alter the HRs. Moreover, brain
atriuretic peptide has been shown to predict long-term
ortality independently of the presence of clinical evidence
f heart failure (16).
TnT and CRP. Admission cTnT and CRP were not
redictive in the multivariate analyses. This in part may be
he result of redundancy between several biomarkers. Re-
arding cTnT, a major limitation of this assay is the low
ensitivity at admission because of a delayed increase in
irculating levels (17), typically peaking several hours after
evascularization. An elevation in CRP levels can be dis-
erned approximately 16 h after the onset of symptoms (18).
omplicating the assessment of CRP is the observation that
igher admission CRP values are observed in patients with
reinfarction unstable angina, compared with those with an
nheralded MI (19). We appreciate that assessment of
TnT and CRP at admission does not fully represent the
otential prognostic value provided by later assessments.
owever, our current model is based on admission data and
rovides valuable prognostic information at the start of
PCI.
ultimarker score. Our multimarker score stratified
TEMI patients into low-, intermediate-, and high-risk
ubgroups concerning long-term mortality. Patients were
dmitted a mean of 2 h after onset of symptoms. Although
iomarkers were measured at a later time point offline in our
tudy, such results could have been available during the
PCI procedure with rapid bedside tests. The main advan-
age of this multimarker score is its simplicity and strong
iscriminative capacity. When confirmed by other indepen-
ent cohorts (20), our multimarker score may be useful in
dentifying patients eligible for adjuvant therapies during or
fter PPCI. This is particularly important in view of the
umber of new treatments investigated in STEMI patients,
uch as ticagrelor and delta-protein kinase C inhibitors
21,22), potentially leading to resource-limited treatment
ptions.Finally, the use of coronary intervention, fibrinolytic or
ntithrombotic therapy, and secondary prevention have led
o a low mortality rate after STEMI. This means that very
arge clinical trials would need to be powered adequately to
how a mortality benefit for promising new adjunctive
herapies. Focusing on the high-risk subgroup may assist in
esigning modestly size, but adequately powered, trials.
tudy limitations. Several limitations of the current study
eserve mention. First, there is a potential selection bias
ecause of 306 excluded patients with missing or incomplete
iomarkers. We assume that this limitation has not signif-
cantly influenced our results, because no major differences
ere observed in baseline characteristics of included and
xcluded patients. In the adjusted multimarker, 279 patients
ere excluded because of missing established risk factor
ata. However, there were no statistically significant differ-
nces between included and excluded patients with the
xception of more prior coronary artery bypass grafting
rocedures in the excluded patients. Second, the single use
f data from our PCI center could have caused further
election of patients. Third, the established prognostic
actors used in our analyses were derived from the throm-
olysis in myocardial infarction risk score (1). Although the
hrombolysis in myocardial infarction risk score was derived
rom a clinical trial population instead of a real-world
opulation, this score has been validated in a community-
ased STEMI population (23). Finally, information on vital
tatus was obtained from the Dutch national population
egistry, wherein information on the cause of death is not
vailable.
onclusions
ur data suggest that the sole use or addition of a
ultimarker to a model including established risk factors
mproves the prediction of mortality in STEMI patients
ndergoing PPCI.
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APPENDIX
or a table on the hazard ratios of the quartiles per biomarker in
nivariable Cox regression, please see the online version of this article.
